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Abstract 
 
The human breast undergoes lifelong remodeling in response to estrogen and progesterone, but 
hormone exposure also increases breast cancer risk. Here, we use single-cell analysis to identify distinct 
mechanisms through which breast composition and cell state affect hormone signaling. We show that 
prior pregnancy reduces the transcriptional response of hormone-responsive (HR+) epithelial cells, 
whereas high body mass index (BMI) reduces overall HR+ cell proportions. These distinct changes both 
impact neighboring cells by effectively reducing the magnitude of paracrine signals originating from HR+ 
cells. Because pregnancy and high BMI are known to protect against hormone-dependent breast cancer 
in premenopausal women, our findings directly link breast cancer risk with person-to-person 
heterogeneity in hormone responsiveness. More broadly, our findings illustrate how cell proportions and 
cell state can collectively impact cell communities through the action of cell-to-cell signaling networks. 
 
Introduction 
 
The rise and fall of estrogen and progesterone with each menstrual cycle and during pregnancy controls 
cell growth, survival, and tissue morphology in the human breast. The impact of these changes is 
profound, and lifetime exposure to cycling hormones is a major modifier of breast cancer risk (1). In 
addition to the dynamics observed within individuals in response to changing hormone levels, there is 
also a high degree of heterogeneity between individuals in epithelial architecture (2), cell composition (3), 
and hormone responsiveness (4-6), and these differences likely impact breast cancer susceptibility. 
However, because the breast is both highly variable between women and undergoes dynamic changes 
over time, it has been difficult to link differences in breast cancer risk with specific biological mechanisms 
in the breast. 
 
One approach has been to identify specific cellular and molecular changes associated with established 
breast cancer risk factors identified by epidemiological studies. Reproductive history and body mass 
index (BMI) are two factors that strongly influence breast cancer risk. Pregnancy has two opposing 
effects: it increases short-term risk by up to 25% (7) but decreases lifetime risk by up to 50%, particularly 
for women with a first pregnancy early in life (8). Obesity has opposing effects on risk before versus after 
menopause: it increases postmenopausal risk by around 30% (9) but decreases premenopausal risk by 
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up to 45% (10, 11). The protective effects of both BMI and pregnancy are strongest for estrogen- and 
progesterone-receptor positive (ER+/PR+) breast cancers (11, 12), suggesting that altered hormone 
signaling is one mechanism contributing to the tumor-protective effect of these two factors. The 
mechanistic link between pregnancy and the long-term reduction in breast cancer risk remains an open 
question, but it has been speculated that the effects of pregnancy-induced alveolar differentiation—such 
as changes in the epithelial architecture of the mammary gland or a general decrease in the hormone 
responsiveness of the epithelium—may contribute to reduced risk (2, 8). While estrogen production by 
adipose tissue is a major mechanism proposed to contribute to the increased risk of postmenopausal 
breast cancer in obese women (13), far less is known about the underlying mechanisms that link obesity 
and the decreased risk of ER/PR+ premenopausal breast cancer. 
 
One challenge for understanding the relationship between hormone signaling, pregnancy, and BMI in the 
healthy human breast is that many of the effects of ovarian hormones within the breast are indirect. The 
estrogen and progesterone receptors (ER/PR) are expressed in only 10-15% of hormone-responsive 
(HR+) luminal cells within the epithelium (14), and most of the effects of hormone receptor activation are 
mediated by a complex cascade of paracrine signaling from HR+ luminal cells to other cell types in the 
breast. Thus, decreased hormone responsiveness in the parous breast could reflect either: 1) a change 
in the hormone signaling response of HR+ luminal cells—due to either changes in HR+ luminal cells 
themselves or non-cell autonomous changes in hormone levels or availability—and/or 2) a reduction in 
the proportion of HR+ luminal cells, leading to dampened paracrine signaling to other cell types 
downstream of ER/PR activation. Single-cell RNA sequencing (scRNAseq) is particularly well-suited to 
investigate this problem, since it enables unbiased classification of the full repertoire of cell types within 
the human breast together with their transcriptional state. 
 
Here, we use scRNAseq of twenty-eight premenopausal reduction mammoplasty tissue specimens, 
together with FACS and immunostaining in an expanded cohort (Table S1), to directly measure sample-
to-sample variability in cell proportions and cell signaling state in the breast. We develop a computational 
approach that leverages the inter-sample transcriptional heterogeneity in our dataset to identify 
coordinated changes in transcriptional states across cell types in the breast. Based on this, we identify a 
set of correlated gene expression programs in HR+ luminal cells and other cell types representing the 
paracrine signaling network activated in response to hormones. Second, we find that prior history of 
pregnancy is associated with striking changes in epithelial composition, and we propose that these 
changes are consistent with the protective effect of pregnancy on lifetime breast cancer risk. Finally, we 
show that pregnancy and obesity both lead to decreased hormone response in the breast through two 
distinct mechanisms: pregnancy directly affects hormone signaling in HR+ luminal cells whereas obesity 
reduces the proportion of HR+ luminal cells. Overall, these results provide a comprehensive map of the 
cycling human breast and identify cellular changes that underlie breast cancer risk factors. 
 
Results 
 
Inter-sample variability in epithelial cell proportions and transcriptional cell state in the human breast 
 
To identify inter-individual differences in cell composition and cell state in the human breast, we 
performed scRNAseq analysis on 86,136 cells from reduction mammoplasties in 28 premenopausal 
donors (Fig. 1A and table S1). To obtain an unbiased snapshot of the epithelium and stroma, we collected 
live/singlet cells for all samples. For a subset of samples, we also collected epithelial cells or purified 
luminal and basal/myoepithelial cells (fig. S1A, table S2). We used MULTI-seq barcoding and in silico 
genotyping for sample multiplexing to minimize technical variability between samples (fig. S1B, methods) 
(15, 16). 
 
Sorted basal and luminal cell populations were well-resolved by uniform manifold approximation and 
projection (UMAP) (fig. S1C). Unsupervised clustering identified one myoepithelial/basal cluster, two 
luminal clusters, and six stromal clusters (Fig. 1B). Based on the expression of known markers, the two 
luminal clusters were annotated as hormone-responsive (HR+) and secretory luminal cells, and the six 
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stromal clusters were annotated as fibroblasts, blood endothelial cells, lymphatic cells, vascular 
accessory cells, lymphocytes, and macrophages (Fig. 1B and fig S2A-B). The luminal populations 
described here closely match those identified as “hormone-responsive/L2” and “secretory/L1” in a 
previous scRNAseq analysis of the human breast (17), as well as microarray data for sorted 
EpCAM+/CD49f– “mature luminal” and EpCAM+/CD49f+  “luminal progenitor” populations (18). Here, we 
use the nomenclature hormone-responsive/HR+ and secretory to refer to these two cell types. The HR+ 
cluster was enriched for the hormone receptors ESR1 and PGR (fig. S2C), and other known markers 
such as ANKRD30A (fig. S2A-B) (17). Consistent with previous studies demonstrating variable hormone 
receptor expression across the menstrual cycle (19), expression of ESR1 and PGR transcripts were 
sporadic and often non-overlapping. Within the HR+ luminal cluster, 22% of the cells had detectable 
levels of ESR1 or PGR, with only 2% of cells expressing both transcripts (fig. S2D).  
 
Beyond identifying the major cell types, single-cell analysis additionally resolved two sources of inter-
sample variability in the human breast. First, while cells from different individuals were represented 
across all clusters (cluster entropy = 0.93, methods) (fig. S3A), the proportions of epithelial cell types 
were highly variable between samples (Fig. 1C). Across individuals, epithelial cell proportions in the 
live/singlet and epithelial sort gates ranged from 2-80% for basal/myoepithelial cells, from 7-89% for HR+ 
luminal cells, and from 9-70% for secretory luminal cells (fig. S3B). Second, independent of variation in 
cell proportions, individuals displayed distinct transcriptional signatures within cell types (Fig. 1D and fig 
S3C). This variation in cell state was not due to technical variability across batches (table S2), as cells 
from the same sample were more similar to each other than cells from different samples, regardless of 
the day of processing (fig. S3, D and E, methods).  
 
Parity is associated with an increased proportion of basal/myoepithelial cells in the epithelium 
 
The breast undergoes a major expansion of the mammary epithelium during pregnancy, followed by a 
regression back towards the pre-pregnant state after weaning in a process called involution. However, 
the epithelial architecture remains distinct from that of women without prior pregnancy, consisting of 
larger terminal ductal lobular units (TDLUs) containing greater numbers of acini. At the same time, 
individual acini are reduced in size (2). We hypothesized that these architectural changes would be a 
major driver of differences in epithelial cell proportions between samples in our dataset.  
 
We focused our initial analysis on the 63,583 cells in the live/singlet and epithelial sort gates to get an 
unbiased view of how the epithelial composition of the breast changes with pregnancy. The proportion of 
basal/myoepithelial cells in the epithelium was approximately two-fold higher in women with prior history 
of pregnancy (parous) relative to women without prior pregnancy (nulliparous) (Fig. 2A and fig. S4A). We 
confirmed these results in an expanded cohort of samples using three additional methods. First, we 
measured basal cell proportions by flow cytometry analysis of EpCAM and CD49f. Consistent with 
clustering results, parity was associated with an increase in the average proportion of basal cells from 
12% to 39% of the epithelium (Fig. 2B). The proportion of basal cells did not vary with other discriminating 
factors such as BMI, race, or hormonal contraceptive use (HC), but was weakly associated with age (R2 
= 0.20, p < 0.04) (fig. S4B). To determine the relative effect of each factor, we performed multiple linear 
regression analysis and found that the basal cell fraction positively correlated with pregnancy history (p 
< 2e-05), but not age (p = 0.17) (Table S3). Next, as FACS processing steps may affect tissue 
composition, we performed two further analyses. We reanalyzed previously published microarray 
datasets of total RNA isolated from core needle biopsies from premenopausal (n = 71 parous/ 42 
nulliparous) or postmenopausal (n = 79 parous/ 30 nulliparous) women (20, 21), and confirmed a 
significant increase in the basal/myoepithelial markers KRT5, KRT14, and TP63 relative to luminal 
markers in parous samples (fig. S4C). Finally, we performed immunostaining and confirmed an 
approximately 2-fold increase in the ratio of p63+ basal cells to KRT7+ luminal cells in intact tissue 
sections (Fig. 2C). Notably, staining demonstrated that this change in epithelial proportions was specific 
to TDLUs rather than ducts (fig. S5A). We hypothesized that the increased frequency of 
basal/myoepithelial cells observed in parous women could be explained, in part, by changes in TDLU 
architecture. To test this, we performed a morphometric comparison of TDLUs between parous and 
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nulliparous samples in our dataset. Consistent with previous reports (2), we observed a marked decrease 
in the average diameter of individual acini in parous women (fig. S5B). Additionally, we found that the 
average thickness of the luminal cell layer was linearly associated with acinus diameter (fig. S5C) and 
reduced in parous women (fig. S5D).  
 
To determine how these parameters influence the relative proportions of each cell type, we implemented 
a simple geometric model. Based on our measurements, we modeled each acinus in two dimensions as 
a hollow circle with a shell thickness linearly proportional to its diameter (Fig. 2D). Since basal cells form 
a monolayer along the luminal surface, we represented the space available for basal cells as the outer 
perimeter of the luminal layer, and the space available for luminal cells as the area of the luminal layer. 
Surprisingly, when normalized to cross-sectional area (for luminal cells) or perimeter (for basal cells), 
there was no change in luminal cell density or basal cell coverage between parous versus nulliparous 
samples (Fig. 2E and fig. S5E). Across all samples, the number of basal or luminal cells per acinus was 
directly proportional to the space available for each cell type (fig. S5F). However, geometric modeling 
accurately predicted the relationship between the luminal area and outer perimeter for individual acini 
(mean absolute percentage error loss = 9.5%) and demonstrated that as individual acini increased in 
size, the space available for luminal cells increased at a faster rate than the space available for basal 
cells (Fig. 2F). Thus, geometric constraints underlie at least part of the observed differences in epithelial 
cell proportions between parous and nulliparous samples.  
 
Obesity is associated with a reduction in the proportion of HR+ luminal cells 
 
While parity was associated with a decreased overall proportion of luminal cells in the epithelium, the 
proportions of individual HR+ and secretory subtypes within the luminal compartment were highly 
variable. Consistent with previous work (5, 22), we observed reduced frequencies of HR+ luminal cells 
in parous women (p < 0.03). However, the proportion of secretory luminal cells was not associated with 
parity (fig. S4A). Together, these data suggested that additional factors influence the relative proportion 
of HR+ versus secretory cells within the luminal compartment. We therefore performed multiple 
comparison analysis to test for the effects of parity, BMI, race, age, and hormonal contraceptive use on 
the proportions of HR+ versus secretory cells in the luminal compartment. We found that the relative 
proportion of HR+ luminal cells was reduced in obese women (BMI > 30) (Fig. 3A) but did not vary with 
other discriminating factors such as age, reproductive history, hormonal contraceptive use, or race (fig. 
S6A). On a continuous scale, each 12 units of BMI was associated with a 2-fold reduction in the proportion 
of HR+ cells in the luminal compartment (fig. S6B). We observed similar results using clustering analysis 
from the 10,795 cells in the luminal sort gate (fig. S6C). 
 
One limitation of the reduction mammoplasty dataset was that all samples classified as non-obese were 
from nulliparous women less than 24 years old, whereas obese samples were more likely to be from 
parous and older age women (table S1). Therefore, we performed scRNAseq analysis on an independent 
set of breast core biopsies from healthy premenopausal women who donated tissue to the Komen Tissue 
Bank (KTB). In contrast with the reduction mammoplasty cohort, the KTB cohort consisted of older (37-
47 years) parous samples with BMI in the normal or overweight range (BMI 20.7-28.3) (table S1, fig. 
S7A). We used MULTI-seq for sample multiplexing and collected pooled live/singlet and epithelial cells 
(fig. S7B). Unsupervised clustering identified one myoepithelial/basal cell cluster, two luminal cell 
clusters, and five stromal clusters (fig. S7C). As in our previous analysis, the two luminal clusters were 
identified as HR+ and secretory luminal cells based on the expression of known markers (fig. S7, D and 
E). Using the reduction mammoplasty cohort as a training set, we accurately predicted the proportion of 
HR+ luminal cells in the KTB cohort with a mean absolute percentage error of 14.8% (Fig. 3B). 
 
To verify these results in tissue sections, we performed immunostaining for ER and PR. There was a 
trend toward decreased expression of PR with increasing BMI, but the change was not statistically 
significant (p = 0.11, fig. S8A). Notably, ER and PR expression was variable and partly non-overlapping, 
ranging from 11-71% overlap (fig. S8B). As we had previously also observed heterogeneous expression 
of ESR1 and PGR transcripts within the HR+ luminal cell cluster (fig. S2, C and D), we hypothesized that 
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the variability in staining was due to changes in ER and PR expression, stability, and nuclear localization 
that have all been previously observed based on hormone receptor activation status (19, 23, 24).  
 
Based on this, we predicted that ER/PR transcript and protein expression levels would co-vary across 
samples due to the overall proportion of HR+ luminal cells and the hormonal microenvironment, but would 
be stochastically expressed in individual cells at any one time due to dynamic fluctuations in mRNA and 
protein expression and stability. To test this, we performed co-immunostaining and RNA-FISH and 
confirmed that although ER transcript and protein levels correlate across tissue sections, they do not 
correlate on a per-cell basis—on average, only 31% of cells expressing ESR1 transcript also expressed 
ER protein (fig. S8C). Importantly, our scRNA-seq analysis demonstrated that the expression of ESR1 
or PGR transcript was highly specific for cells in the HR+ luminal cluster, although the overall proportion 
of HR+ cells that expressed each transcript was low and varied across individuals (fig. S8D). Thus, these 
data demonstrate that immunostaining for nuclear hormone receptors underestimates the fraction of cells 
in the HR+ lineage and that lack of ER/PR expression cannot be used to reliably define a cell as part of 
the secretory versus HR+ luminal cell lineage.  
 
On the basis of these results, we sought to identify another marker to distinguish between luminal 
subpopulations, and identified keratin 23 (KRT23) as highly enriched in the secretory luminal cell cluster 
(Fig. 3C), as was also reported by a previous scRNAseq study (17). Immunohistochemistry for KRT23 
and PR or ER confirmed that these proteins are expressed in mutually exclusive luminal populations (Fig. 
3D, and fig. S9, A and B). The proportion of KRT23+ luminal cells in each sample was also highly 
correlated with the proportion of secretory luminal cells identified by scRNAseq (fig. S9C). KRT23 thus 
represents a discriminatory marker between the two luminal populations. Staining in intact tissue sections 
confirmed that the proportion of KRT23+ secretory luminal cells increased by about 17% for every 10-
unit increase in BMI (Fig. 3E). Together, these data demonstrate that there are two independent effects 
of reproductive history and body weight on cell proportions in the mammary epithelium: parity affects the 
ratio of basal to luminal cells whereas BMI affects the ratio of HR+ versus secretory luminal cells (Fig. 
3F).  
 
Hormone signaling is a primary axis of transcriptional variability in HR+ luminal cells 
 
Beyond differences in cell proportions, we found that transcriptional cell state within clusters was a 
second source of inter-sample variability in our dataset (Fig. 1D, and fig. S3, C, D, and E). Since estrogen 
and progesterone are master regulators of breast development, we hypothesized that hormone signaling 
would represent a major source of transcriptional heterogeneity. Consistent with this, we previously 
observed a high degree of sample-to-sample variation in ER/PR expression (fig. S8D) within the HR+ 
luminal cell cluster, which has been shown to vary based on hormone receptor activation state (19, 23, 
24). 
 
To quantify cell state in HR+ luminal cells, we performed principal component (PC) analysis on this 
population. Analysis of ranked gene loadings demonstrated that variation across PC1 in HR+ cells was 
driven by genes involved in the response to hormone receptor activation, including the essential PR target 
genes TNFSF11 (RANKL) and WNT4 (6, 25) (Fig. 4A). Of the 20 genes with the highest loadings in PC1, 
12 have been previously described as associated with either progesterone signaling, estrogen signaling, 
or the luteal phase of the menstrual cycle when progesterone is at its peak (fig. S10A, table S4) (6, 26-
35). Thus, transcriptional changes associated with hormone signaling state (PC1) are a dominant source 
of variation in HR+ luminal cells (fig. S10B). 
 
As PC analysis seeks to maximize the variance of a projected dataset, it may combine gene signatures 
from multiple transcriptional states into a single component (36). Therefore, we performed non-negative 
matrix factorization (NMF) to identify a specific gene signature of hormone signaling, and identified 9 
distinct gene expression programs, or “metagenes” in HR+ luminal cells (Fig. 4B, and fig. S10, C and D) 
{Welch:2019dz, Yang:2016fu}. Cell embedding in PC1 was highly correlated with expression of 
metagene 8 (Pearson correlation = 0.79, fig. S10E). Analysis of ranked gene loadings demonstrated that 
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this “hormone signaling” metagene comprised a similar gene expression program as PC1, including the 
PR targets TNFSF11 and WNT4 and the ER target TFF3 (Fig. 4B). The hormone signaling metagene 
was enriched for genes upregulated during the luteal phase of the menstrual cycle (Fig. 4C) (29), and for 
transcripts in the Molecular Signatures Database Hallmark “early estrogen response” and “late estrogen 
response” gene sets (fig. S10F) (39). Thus, NMF identified a distinct transcriptional signature for hormone 
receptor activation in HR+ luminal cells. 
 
The hormone signaling response of HR+ luminal cells is reduced in parous women 
 
Previous epidemiologic analyses have demonstrated that the protective effect of parity against breast 
cancer is specific for ER+/PR+ tumors (40). Decreased hormone responsiveness following pregnancy is 
one proposed mechanism for this effect (8). Supporting this, previous studies demonstrated decreased 
expression of the PR effector WNT4 following pregnancy (5, 22, 41). Moreover, in an explant culture 
model, estrogen induced expression of the ER target gene AREG only in nulliparous women (4). As the 
effects of hormones in the breast are primarily mediated by paracrine signaling from HR+ luminal cells, 
this decreased hormone responsiveness could be caused by either: 1) a change in the magnitude of 
paracrine signals produced by each HR+ luminal cell, and/or 2) a reduction in the overall proportion of 
HR+ luminal cells leading to a “dilution” of paracrine signals following ER/PR activation. It has been 
difficult to distinguish between these mechanisms using tissue-level analyses. By probing the single-cell 
transcriptional landscape of the HR+ luminal cell population, NMF analysis provides a means to directly 
interrogate whether parity influences the per-cell hormone signaling response of HR+ luminal cells.  
 
To quantify variation in hormone signaling, we first measured the similarity between each sample’s single-
cell distribution across metagene 8. Hierarchical clustering identified two sets of samples, representing 
high or low hormone signaling (fig. S11A). Based on this, we found that while the level of hormone 
signaling in HR+ luminal cells varied between nulliparous women, likely reflecting changing hormone 
levels across the menstrual cycle, per-cell hormone signaling in HR+ luminal cells was significantly 
reduced in parous women (Fig. 4D, and fig. S11B). To identify differentially expressed genes between 
nulliparous and parous women with high sensitivity, we generated a pseudo-bulk dataset of aggregated 
HR+ luminal cells from each sample (Methods) and confirmed that parous women had decreased 
expression of the canonical hormone-responsive genes TFF1, PGR, WNT4, TNFSF11, and AREG (fig. 
S11C, table S5). Notably, the progesterone receptor itself is an ER target gene (42). Staining for the 
progesterone receptor and K23 confirmed that PR expression was reduced in the HR+ luminal cell 
subpopulation (K7+/K23-) of parous samples (fig. S11D).  
 
Finally, we confirmed that paracrine signaling downstream of PR activation was specifically reduced in 
parous samples by assessing the effects of one of these genes, WNT4. As WNT4 from HR+ luminal cells 
has been shown to signal to basal cells (25), we performed co-immunostaining for the WNT effector 
TCF7 and basal cell marker p63 and found that TCF7 expression was markedly decreased in parous 
samples (Fig. 4E). This decrease was not due to differences in epithelial architecture, as TCF7 staining 
in ducts versus TDLUs within the same samples was unchanged (fig. S11E). Together, these data 
demonstrate that transcriptional variation among HR+ luminal cells is primarily related to hormone 
signaling, that transcription along this axis (HR+ metagene 8) is reduced in women with prior history of 
pregnancy, and that these transcriptional changes coincide with a reduction in downstream paracrine 
signaling to basal cells. 
 
Identification of coordinated changes in signaling states across cell types in the breast 
 
The above results established that parity was associated with a change in the per-cell hormone signaling 
of HR+ luminal cells. As the global effects of ER/PR activation in the breast are controlled by paracrine 
signaling from HR+ luminal cells to other cell types, we reasoned that hormone receptor activation in 
HR+ luminal cells would be linked to transcriptional changes in other cell types representing the 
downstream paracrine response. To identify putative transcriptional signatures of the paracrine response, 
we developed a computational framework that leverages the person-to-person transcriptional 
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heterogeneity observed within cell types to find coordinated changes in cell signaling states across 
samples. First, we decomposed each cell type into a set of distinct gene expression programs, or 
“metagenes”, using NMF as described above (fig. S10, C and D, and fig. S12, A and B). We then 
quantified the average expression of each metagene for each sample and constructed a weighted 
network of coordinated gene expression programs based on the pair-wise Pearson correlations between 
metagenes (fig. S12C, methods). Finally, we identified modules of highly correlated gene expression 
programs using the infomap community detection algorithm (43). Using this approach, we identified three 
major modules—annotated here as “resting state”, “paracrine signaling”, and “involution” modules—
comprising highly interconnected transcriptional states across cell types in the breast (Fig. 5A).  
 
The “resting state” module consisted of gene expression programs that were anti-correlated with 
hormone signaling in HR+ luminal cells (Fig. 5A, and fig. S13A). Metagenes in this module were primarily 
enriched for pathways involved in ribosome biogenesis and mRNA processing (fig. S14B). The “paracrine 
signaling” module comprised gene expression programs that were positively correlated with hormone 
signaling in HR+ luminal cells (Fig. 5A, and fig. S14A). As expected based on the central role HR+ cells 
play in the response to estrogen and progesterone, the HR+ hormone signaling metagene (HR+ 
metagene 8) had the greatest influence on information flow within this module, as measured by 
betweenness centrality (fig. S14A). Our analysis revealed that high levels of hormone signaling in HR+ 
cells coincided with the emergence of a second transcriptional state—HR+ metagene 5—in a distinct 
subpopulation of HR+ luminal cells (fig. S14B). Marker analysis and gene set enrichment analysis 
demonstrated that HR+ metagene 5 was characterized by upregulation of a hypoxia gene signature and 
pro-angiogenic factors such as VEGFA and ANGPTL4 (fig. S14C). Interestingly, a previous study using 
microdialysis of healthy human breast tissue found that VEGF levels increased in the luteal phase of the 
menstrual cycle (44). As estrogen response elements have been identified in the untranslated regions of 
VEGFA (45), our results suggest that this increased expression may be, in part, a direct effect of hormone 
signaling to this subpopulation of HR+ cells. 
 
We next investigated gene expression programs in other epithelial and stromal populations that 
correlated with hormone signaling in HR+ luminal cells. NMF and network analysis identified a 
subpopulation of proliferative secretory luminal cells within the paracrine signaling module (fig. S12B, 
and fig. S14D). This “proliferation” metagene was highly enriched for cell-cycle related genes previously 
found to be upregulated during the luteal phase of the menstrual cycle (fig. S14E) (29). Moreover, similar 
to HR+ cells, basal/myoepithelial cells in samples with high levels of hormone signaling had enrichment 
of transcripts involved in hypoxia and angiogenesis such as VEGFA and ANGPTL4 (fig. S14F). Gene set 
enrichment analysis demonstrated that variation across this basal cell “paracrine response” metagene 
was driven by genes involved in epithelial-mesenchymal transition, cell motility, and extracellular matrix 
(ECM) organization (fig. S14F), suggesting that changes in actomyosin contractility and cell-ECM 
interactions underlie the previously reported morphological changes observed in the breast epithelium 
across the menstrual cycle (46). Finally, previous studies have identified alterations in stromal 
organization and ECM composition across the menstrual cycle (47, 48). Consistent with this, hormone 
signaling in HR+ luminal cells correlated with two distinct gene expression programs in fibroblasts: a 
“tissue remodeling” metagene characterized by upregulation of ECM proteins including collagens 
(COL3A1, COL1A1, COL1A2) and fibronectin (FN1), and a “proinflammatory” gene expression program 
representing upregulation of cytokines and growth factors such as IL6 and TGFB3 (fig. S14G).  
 
Finally, gene set enrichment analysis of the third module uncovered a transcriptional signature in HR+ 
and secretory luminal cells that was similar to that identified during post-lactational involution (fig. S15, A 
and B) (49, 50). These “involution” metagenes were characterized by high expression of death receptor 
ligands such as TNFSF10 (TRAIL) and genes involved in the defense and immune response, including 
interferon-response genes (fig. S15, B and C). The involution signature in secretory luminal cells was 
also characterized by expression of major histocompatibility complex class II (MHCII) molecules and the 
phagocytic receptors CD14 and MARCO (fig. S15B), suggesting that these cells play a role as non-
professional phagocytes in the clearance of apoptotic cells, similar to what has been described during 
involution (51). Previous data have demonstrated that the fraction of apoptotic cells in the mammary 
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epithelium peaks between the late luteal and early follicular phases of the menstrual cycle (52). Notably, 
TGFB3 signaling is a major signaling molecule involved in post-lactational involution that enhances 
phagocytosis by mammary epithelial cells (53), suggesting that TGFB3 secreted by fibroblasts at the end 
of the luteal phase (fig. S14G) activates a subset of secretory luminal cells during the late luteal/early 
follicular phase that go on to express “involution” markers including phagocytic receptors.  
 
Together, these results demonstrate how the underlying sample-to-sample variability in scRNAseq data 
can be used to infer cell-cell communication networks. Using this computational framework, we find that 
paracrine signaling from HR+ luminal cells is a driver of transcriptional variability across all major cell 
types in the breast. Strikingly, many of these changes closely mimic those seen during the 
pregnancy/involution cycle that have been linked to a transient increased breast cancer risk following 
pregnancy (54-56). 
 
The proportion of HR+ luminal cells predicts basal cell paracrine signaling state  
 
Previously, we demonstrated that parity was associated with a change in the per-cell hormone signaling 
response of HR+ luminal cells (Fig. 4D), whereas increased BMI was associated with a reduction in the 
proportion of HR+ cells in the luminal compartment (Fig. 3). As the effects of ER/PR activation are 
controlled by paracrine signaling from HR+ luminal cells to other cell types, we reasoned that the overall 
proportion of HR+ luminal cells in the epithelium was a second mechanism that could affect the hormone 
responsiveness of the breast. While the downstream effects of hormone receptor activation in HR+ 
luminal cells are controlled by a complex set of signaling networks, previous work has shown that HR+ 
cells signal directly to basal cells via WNT (25). Since WNT proteins generally form short-range signaling 
gradients (57), we predicted that the paracrine signaling response in basal cells would be particularly 
sensitive to reductions in the proportion of HR+ luminal cells. Consistent with this idea, while the basal 
cell “paracrine response” metagene was linearly associated with the hormone signaling state of HR+ 
luminal cells (R2 = 0.57, p < 3e-6), positive outliers tended to have a greater proportion of HR+ luminal 
cells and negative outliers tended to have a lower proportion of HR+ luminal cells in the epithelium (Fig. 
5B). 
 
To formally test this prediction, we modeled the basal cell paracrine response as a linear response to 
three variables: HR+ cell hormone signaling, the frequency of HR+ cells in the epithelium, and an 
interaction term representing the combined effects of HR+ signaling and frequency (Signaling × 
Frequency). This combined model accounted for over 75% of the sample-to-sample variation across the 
paracrine response metagene in basal cells (Fig. 5C, fig. S16A, and table S6; p < 3e-8). Importantly, only 
the interaction term (Signaling × Frequency) was a significant predictor of basal cell transcriptional state 
(Fig. 5C and table S6), demonstrating that the basal cell paracrine response requires both hormone 
signaling in HR+ cells and an appreciable abundance of HR+ cells in the epithelium. Together, these 
results are consistent with a model in which the proportion of HR+ luminal cells in the epithelium 
influences the magnitude of paracrine signaling to basal cells downstream of estrogen and progesterone. 
 
Based on these results, we predicted that BMI would influence paracrine signaling from HR+ luminal cells 
to basal cells, since HR+ luminal cells are reduced in obese women (Fig. 3). Confirming this, we found 
that while direct hormone signaling in HR+ cells was not significantly affected by obesity (fig. S16B), the 
downstream basal cell paracrine response was significantly reduced in obese samples (Fig. 5D). 
Consistent with the reduced hormone signaling previously observed in HR+ cells from parous women 
(Fig. S4D), parity was also associated with a reduction in the basal cell paracrine response (Figs. S16C). 
 
Gene set enrichment analysis demonstrated that variation in the basal cell “paracrine signaling” 
metagene was driven by genes involved in contractility and cell motility (fig. S14F). To determine whether 
these genes were differentially expressed in obese and/or parous women, we generated a “pseudo-bulk” 
dataset of basal cells from each sample. Of the 195 genes significantly downregulated in parous samples 
and 148 genes significantly downregulated in obese samples, 68 were reduced across both groups (fig. 
S16D and table S7). Both parous and obese samples had decreased expression of contractility-related 
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genes including ACTA2, ACTG2, CNN1, MYH11, MYL9, and MYLK, as well as the basement membrane 
proteins COL4A1 and COL14A1 (fig. S16D and table S7). Finally, consistent with the idea that parity and 
obesity reduce the paracrine response of basal cells to hormone signaling, expression of the WNT target 
genes SPP1 and WLS were also reduced in both subsets. Overall, these results are consistent with a 
model in which parity and BMI affect the hormone responsiveness of the breast through two distinct 
mechanisms: parity directly alters the hormone signaling response in HR+ luminal cells, whereas BMI 
indirectly affects hormone signaling by reducing the proportion of HR+ luminal cells in the mammary 
epithelium (Fig. 5E). 
 
Discussion 
 
In this study, we combine single-cell analyses, immunostaining, and computational modeling to 
understand the major sources of sample-to-sample heterogeneity in the human breast. Importantly, by 
using single-cell measurements, we were able to separate out the effects of variation in cell proportions 
from variation in transcriptional state. Second, we describe a computational pipeline that leverages the 
inter-sample transcriptional heterogeneity in our dataset to identify coordinated changes in cell signaling 
states across cell types. Using this approach, we identify a set of highly correlated gene expression 
programs representing the in situ response to hormone receptor activation in HR+ cells and downstream 
signaling in other cell types. Furthermore, we show that person-to-person heterogeneity in hormone 
responsiveness in the breast is directly linked to two factors known to modulate premenopausal breast 
cancer risk—reproductive history and BMI.  
 
Pregnancy has a pronounced protective effect against breast cancer, with up to a 50% reduction in breast 
cancer risk for women with multiple full-term pregnancies at a young age (8). Our analysis revealed that 
parity is associated with a stark increase in the proportion of basal and/or myoepithelial cells within the 
breast epithelium. Previous work has described two tumor-protective features of myoepithelial cells: they 
are highly resistant to malignant transformation (58-61) and also act as a natural and dynamic barrier 
that prevents tumor cell invasion (62, 63). Thus, our data suggest that pregnancy protects against breast 
cancer risk both by decreasing the relative frequency of luminal cells—the tumor cell-of-origin for most 
breast cancer subtypes (58, 64, 65)—and by suppressing progression to invasive carcinoma. 
 
Hormone exposure is another major determinant of breast cancer risk (1, 66-68). Here, we use matrix 
decomposition and network analysis to map the coordinated changes in cell state that occur in response 
to paracrine signaling from HR+ luminal cells. Strikingly, many of these changes closely mimic those 
seen during the pregnancy/involution cycle that have been linked to a transient increased breast cancer 
risk following pregnancy (54-56). First, we identify a proliferative gene signature in secretory luminal cells 
that is highly correlated with hormone signaling in HR+ luminal cells, consistent with previous studies 
demonstrating that RANKL and WNT control progesterone-mediated epithelial proliferation (69). Second, 
previous studies have shown that the fraction of apoptotic cells in the epithelium peaks between the late 
luteal and early follicular phases (52). Consistent with this, we identify subpopulations of HR+ and 
secretory luminal cells in the cycling premenopausal breast enriched for genes known to be upregulated 
during post-lactational involution (50, 70). Notably, we also observe upregulation of hypoxic gene 
signatures in multiple epithelial and stromal cell types that are highly correlated with hormone signaling 
in HR+ cells. A previous study identified these same pathways as highly enriched following involution in 
the mouse mammary gland. More importantly from the perspective of breast cancer risk, this 
“hypoxia/pro-angiogenic” signature identified breast cancers with increased metastatic activity (70), 
suggesting that these pathways support a permissive tumor microenvironment. 
 
Finally, we find that paracrine signaling from HR+ cells to basal cells depends on both the per-cell 
transcriptional response of HR+ cells to hormones and the overall proportion of HR+ cells in the 
epithelium. Notably, prior pregnancy and obesity are specifically associated with a reduced risk of 
ER+/PR+ breast cancer in premenopausal women (11, 40), and our data support the idea that these 
factors lead to reduced paracrine signaling downstream of estrogen and progesterone via two distinct 
mechanisms. First, parity leads to a reduced per-cell hormone signaling response in HR+ luminal cells. 
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Second, we identify a marked decrease in the ratio of HR+ cells relative to secretory luminal cells with 
increasing BMI. Both changes are associated with a reduced paracrine signaling response in basal cells. 
 
In summary, these results provide a comprehensive, systems-level view of the cellular and transcriptional 
changes that control normal breast development and breast cancer risk in response to cycling hormones. 
This single-cell analysis establishes a link between hormone signaling tumor-promoting changes in cell 
state across multiple cell types. Furthermore, we identify tumor-protective changes in epithelial cell 
proportions and hormone responsiveness with pregnancy and increased body mass. As the breast is one 
of the only human organs that undergoes repeated cycles of morphogenesis and involution, this study 
serves as a roadmap to the cell state changes associated with hormone dynamics in the human breast. 
Finally, it provides a foundation for similar systems-level studies dissecting the how the paracrine 
communication networks downstream of hormone signaling are altered during ER+/PR+ breast cancer 
progression. 
 
Acknowledgments 
 
We thank Drs. Tom Norman and Jonathan Weissman for technical support and for generously providing 
access to equipment and computing resources. Sequencing was performed in the Center for Advanced 
Technology at UCSF. Tissue samples were provided by the Cooperative Human Tissue Network (CHTN), 
which is funded by the National Cancer Institute. Other investigators may have received specimens from 
the same subjects. Samples from the Susan G. Komen Tissue Bank at the IU Simon Cancer Center were 
used in this study. We thank contributors, including Indiana University who collected samples used in this 
study, as well as donors and their families, whose help and participation made this work possible. This 
research was supported in part by grants from the Department of Defense Breast Cancer Research 
Program (W81XWH-10-1-1023 and W81XWH-13-1-0221), NIH (U01CA199315 and DP2 HD080351-01), 
the NSF (MCB-1330864), and the UCSF Center for Cellular Construction (DBI-1548297), an NSF 
Science and Technology Center, to Z.J.G. Z.J.G is a Chan-Zuckerberg BioHub Investigator. L.M.M is a 
Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-2239-15).  
 
Author Contributions 
 
L.M.M., R.J.W., and Z.J.G. conceived the project. L.M.M., J.C., R.J.W., C.S.M., and K.P. performed the 
sequencing experiments. C.S.M. generated aligned reads and barcode matrices, and performed sample 
demultiplexing. P.G. and J.C. coordinated sample acquisition and provided critical guidance for sample 
selection. P.G. and J.C. performed sectioning for fluorescent immunohistochemistry experiments. L.M.M. 
performed fluorescent immunohistochemistry and RNA-FISH experiments. L.M.M. and J.C. performed 
flow cytometry experiments. A.D.B. performed histopathology on tissue sections. L.M.M. analyzed and 
visualized the data. M.T. provided critical guidance in data analyses and computational approaches. T.T. 
and A.D.B. provided critical guidance in human breast biology. T.T., M.T., and Z.J.G. provided critical 
resources. T.A.D., M.T., T.T., and Z.J.G. supervised the project. L.M.M. and Z.G. wrote the manuscript. 
All authors reviewed and edited the manuscript. 
 
 
References 
 
1. Collaborative Group on Hormonal Factors in Breast Cancer, Menarche, menopause, and 
breast cancer risk: individual participant meta-analysis, including 118 964 women with breast 
cancer from 117 epidemiological studies. The Lancet Oncology. 13, 1141–1151 (2012). 
2. J. Russo, R. Rivera, I. H. Russo, Influence of age and parity on the development of the 
human breast. Breast Cancer Res. Treat. 23, 211–218 (1992). 
3. H. Nakshatri, M. Anjanappa, P. Bhat-Nakshatri, Ethnicity-Dependent and -Independent 
Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization. Sci Rep. 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted October 21, 2020. ; https://doi.org/10.1101/430611doi: bioRxiv preprint 
 11 
5, 13526–14 (2015). 
4. K. A. Dunphy et al., Inter-Individual Variation in Response to Estrogen in Human Breast 
Explants. J Mammary Gland Biol Neoplasia. 25, 51–68 (2020). 
5. S. Muenst et al., Pregnancy at early age is associated with a reduction of progesterone-
responsive cells and epithelial Wnt signaling in human breast tissue. Oncotarget. 8, 22353–
22360 (2017). 
6. T. Tanos et al., Progesterone/RANKL is a major regulatory axis in the human breast. Sci 
Transl Med. 5, 182ra55–182ra55 (2013). 
7. M. Lambe et al., Transient increase in the risk of breast cancer after giving birth. N. Engl. J. 
Med. 331, 5–9 (1994). 
8. K. Britt, A. Ashworth, M. Smalley, Pregnancy and the risk of breast cancer. Endocr Relat 
Cancer. 14, 907–933 (2007). 
9. G. K. Reeves et al., Cancer incidence and mortality in relation to body mass index in the 
Million Women Study: cohort study. BMJ. 335, 1134 (2007). 
10. P. A. van den Brandt et al., Pooled analysis of prospective cohort studies on height, weight, 
and breast cancer risk. Am. J. Epidemiol. 152, 514–527 (2000). 
11. Premenopausal Breast Cancer Collaborative Group et al., Association of Body Mass Index 
and Age With Subsequent Breast Cancer Risk in Premenopausal Women. JAMA Oncol. 4, 
e181771 (2018). 
12. R. T. Fortner et al., Parity, breastfeeding, and breast cancer risk by hormone receptor status 
and molecular phenotype: results from the Nurses' Health Studies. Breast Cancer Res. 21, 
40–9 (2019). 
13. M. P. Cleary, M. E. Grossmann, Minireview: Obesity and breast cancer: the estrogen 
connection. Endocrinology. 150, 2537–2542 (2009). 
14. R. B. Clarke, A. Howell, C. S. Potten, E. Anderson, Dissociation between steroid receptor 
expression and cell proliferation in the human breast. Cancer Research. 57, 4987–4991 
(1997). 
15. H. Heaton et al., Souporcell: robust clustering of single-cell RNA-seq data by genotype 
without reference genotypes. Nat Meth. 17, 615–620 (2020). 
16. C. S. McGinnis et al., MULTI-seq: sample multiplexing for single-cell RNA sequencing using 
lipid-tagged indices. Nat Meth. 30, 1 (2019). 
17. Q. H. Nguyen et al., Profiling human breast epithelial cells using single cell RNA sequencing 
identifies cell diversity. Nature Communications. 9, 2028 (2018). 
18. E. Lim et al., Transcriptome analyses of mouse and human mammary cell subpopulations 
reveal multiple conserved genes and pathways. Breast Cancer Res. 12, R21 (2010). 
19. S. Battersby, B. J. Robertson, T. J. Anderson, R. J. King, K. McPherson, Influence of 
menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal 
breast. Br. J. Cancer. 65, 601–607 (1992). 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted October 21, 2020. ; https://doi.org/10.1101/430611doi: bioRxiv preprint 
 12 
20. S. Peri et al., Defining the genomic signature of the parous breast. BMC Med Genomics. 5, 
46 (2012). 
21. J. Santucci-Pereira et al., Genomic signature of parity in the breast of premenopausal 
women. Breast Cancer Res. 21, 1–19 (2019). 
22. F. Meier-Abt, H. Brinkhaus, M. Bentires-Alj, Early but not late pregnancy induces lifelong 
reductions in the proportion of mammary progesterone sensing cells and epithelial Wnt 
signaling. Breast Cancer Res. 16, 209 (2014). 
23. R. Métivier et al., Estrogen receptor-alpha directs ordered, cyclical, and combinatorial 
recruitment of cofactors on a natural target promoter. Cell. 115, 751–763 (2003). 
24. L. N. Petz, A. M. Nardulli, Sp1 binding sites and an estrogen response element half-site are 
involved in regulation of the human progesterone receptor A promoter. Mol. Endocrinol. 14, 
972–985 (2000). 
25. R. D. Rajaram et al., Progesterone and Wnt4 control mammary stem cells via myoepithelial 
crosstalk. The EMBO Journal. 34, 641–652 (2015). 
26. M. C. Abba et al., Gene expression signature of estrogen receptor α status in breast cancer. 
BMC Genomics. 6, 1–13 (2005). 
27. A. Mackay et al., Molecular response to aromatase inhibitor treatment in primary breast 
cancer. Breast Cancer Res. 9, R37–14 (2007). 
28. A. K. Dunbier et al., Relationship between plasma estradiol levels and estrogen-responsive 
gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J. 
Clin. Oncol. 28, 1161–1167 (2010). 
29. I. Pardo et al., Next-generation transcriptome sequencing of the premenopausal breast 
epithelium using specimens from a normal human breast tissue bank. Breast Cancer Res. 16, 
R26 (2014). 
30. H. Hu et al., RANKL expression in normal and malignant breast tissue responds to 
progesterone and is up-regulated during the luteal phase. Breast Cancer Res. Treat. 146, 
515–523 (2014). 
31. Y. Cordeaux, M. Tattersall, D. S. Charnock-Jones, G. C. S. Smith, Effects of 
medroxyprogesterone acetate on gene expression in myometrial explants from pregnant 
women. J. Clin. Endocrinol. Metab. 95, E437–47 (2010). 
32. C. Joyeux, H. Rochefort, D. Chalbos, Progestin increases gene transcription and messenger 
ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol. Endocrinol. 3, 
681–686 (1989). 
33. D. E. Haagensen, P. Stewart, W. G. Dilley, S. A. Wells, Secretion of breast gross cystic 
disease fluid proteins by T47D breast cancer cells in culture — modulation by steroid 
hormones. Breast Cancer Res. Treat. 23, 77–86 (1992). 
34. J. K. Richer et al., Differential gene regulation by the two progesterone receptor isoforms in 
human breast cancer cells. J. Biol. Chem. 277, 5209–5218 (2002). 
35. W. R. Miller, A. Larionov, Changes in expression of oestrogen regulated and proliferation 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted October 21, 2020. ; https://doi.org/10.1101/430611doi: bioRxiv preprint 
 13 
genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the 
aromatase inhibitor, letrozole. Breast Cancer Res. 12, R52–9 (2010). 
36. G. L. Stein-O'Brien et al., Enter the Matrix: Factorization Uncovers Knowledge from Omics. 
Trends Genet. 34, 790–805 (2018). 
37. J. D. Welch et al., Single-Cell Multi-omic Integration Compares and Contrasts Features of 
Brain Cell Identity. Cell. 177, 1873–1887.e17 (2019). 
38. Z. Yang, G. M. Bioinformatics, 2016, A non-negative matrix factorization method for detecting 
modules in heterogeneous omics multi-modal data. academic.oup.com. 
39. A. Liberzon et al., The Molecular Signatures Database (MSigDB) hallmark gene set 
collection. Cell Syst. 1, 417–425 (2015). 
40. H. Ma, L. Bernstein, M. C. Pike, G. Ursin, Reproductive factors and breast cancer risk 
according to joint estrogen and progesterone receptor status: a meta-analysis of 
epidemiological studies. Breast Cancer Res. 8, 3232 (2006). 
41. F. Meier-Abt et al., Parity induces differentiation and reduces Wnt/Notch signaling ratio and 
proliferation potential of basal stem/progenitor cells isolated from mouse mammary 
epithelium. Breast Cancer Res. 15, R36 (2013). 
42. P. Kastner et al., Two distinct estrogen-regulated promoters generate transcripts encoding 
the two functionally different human progesterone receptor forms A and B. The EMBO 
Journal. 9, 1603–1614 (1990). 
43. G. Csardi, T. N. InterJournal, C. systems, 2006, The igraph software package for complex 
network research. researchgate.net. 
44. C. Dabrosin, Variability of vascular endothelial growth factor in normal human breast tissue in 
vivo during the menstrual cycle. J. Clin. Endocrinol. Metab. 88, 2695–2698 (2003). 
45. S. M. Hyder, Z. Nawaz, C. Chiappetta, G. M. Stancel, Identification of functional estrogen 
response elements in the gene coding for the potent angiogenic factor vascular endothelial 
growth factor. Cancer Research. 60, 3183–3190 (2000). 
46. R. Ramakrishnan, S. A. Khan, S. Badve, Morphological changes in breast tissue with 
menstrual cycle. Mod. Pathol. 15, 1348–1356 (2002). 
47. J. E. Ferguson, A. M. Schor, A. Howell, M. W. Ferguson, Changes in the extracellular matrix 
of the normal human breast during the menstrual cycle. Cell Tissue Res. 268, 167–177 
(1992). 
48. G. Hallberg, E. Andersson, T. Naessén, G. E. Ordeberg, The expression of syndecan-1, 
syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle. Reprod. 
Biol. Endocrinol. 8, 35 (2010). 
49. T. Stein et al., Involution of the mouse mammary gland is associated with an immune 
cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer 
Res. 6, R75–91 (2004). 
50. R. W. E. Clarkson, M. T. Wayland, J. Lee, T. Freeman, C. J. Watson, Gene expression 
profiling of mammary gland development reveals putative roles for death receptors and 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted October 21, 2020. ; https://doi.org/10.1101/430611doi: bioRxiv preprint 
 14 
immune mediators in post-lactational regression. Breast Cancer Res. 6, R92–109 (2004). 
51. J. Monks, C. Smith-Steinhart, E. R. Kruk, V. A. Fadok, P. M. Henson, Epithelial cells remove 
apoptotic epithelial cells during post-lactation involution of the mouse mammary gland. Biol. 
Reprod. 78, 586–594 (2008). 
52. T. J. Anderson, D. J. Ferguson, G. M. Raab, Cell turnover in the “resting” human breast: 
influence of parity, contraceptive pill, age and laterality. Br. J. Cancer. 46, 376–382 (1982). 
53. J. Fornetti et al., Mammary epithelial cell phagocytosis downstream of TGF-β3 is 
characterized by adherens junction reorganization. Cell Death Differ. 23, 185–196 (2016). 
54. T. R. Lyons et al., Postpartum mammary gland involution drives progression of ductal 
carcinoma in situ through collagen and COX-2. Nat Med. 17, 1109–1115 (2011). 
55. J. O’Brien et al., Alternatively activated macrophages and collagen remodeling characterize 
the postpartum involuting mammary gland across species. Am. J. Pathol. 176, 1241–1255 
(2010). 
56. P. Schedin, J. O’Brien, M. Rudolph, T. Stein, V. Borges, Microenvironment of the Involuting 
Mammary Gland Mediates Mammary Cancer Progression. J Mammary Gland Biol Neoplasia. 
12, 71–82 (2007). 
57. H. F. Farin et al., Visualization of a short-range Wnt gradient in the intestinal stem-cell niche. 
Nature. 530, 340–343 (2016). 
58. P. J. Keller et al., Defining the cellular precursors to human breast cancer. Proc. Natl. Acad. 
Sci. U.S.A. 109, 2772–2777 (2012). 
59. T. A. Proia et al., Genetic predisposition directs breast cancer phenotype by dictating 
progenitor cell fate. Cell Stem Cell. 8, 149–163 (2011). 
60. S. Koren et al., PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 
Nature Publishing Group. 525, 114–118 (2015). 
61. A. Van Keymeulen et al., Reactivation of multipotency by oncogenic PIK3CA induces breast 
tumour heterogeneity. Nature Publishing Group. 525, 119–123 (2015). 
62. M. D. Sternlicht, P. Kedeshian, Z. M. Shao, S. Safarians, S. H. Barsky, The human 
myoepithelial cell is a natural tumor suppressor. Clin. Cancer Res. 3, 1949–1958 (1997). 
63. O. K. Sirka, E. R. Shamir, A. J. Ewald, Myoepithelial cells are a dynamic barrier to epithelial 
dissemination. J. Cell Biol. 217, 3368–3381 (2018). 
64. L. Melchor et al., Identification of cellular and genetic drivers of breast cancer heterogeneity in 
genetically engineered mouse tumour models. The Journal of Pathology. 233, 124–137 
(2014). 
65. G. Molyneux et al., BRCA1 basal-like breast cancers originate from luminal epithelial 
progenitors and not from basal stem cells. Cell Stem Cell. 7, 403–417 (2010). 
66. E. F. Beaber et al., Recent oral contraceptive use by formulation and breast cancer risk 
among women 20 to 49 years of age. Cancer Research. 74, 4078–4089 (2014). 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted October 21, 2020. ; https://doi.org/10.1101/430611doi: bioRxiv preprint 
 15 
67. V. Beral, Million Women Study Collaborators, Breast cancer and hormone-replacement 
therapy in the Million Women Study. Lancet. 362, 419–427 (2003). 
68. L. S. Mørch et al., Contemporary Hormonal Contraception and the Risk of Breast Cancer. N. 
Engl. J. Med. 377, 2228–2239 (2017). 
69. P. A. Joshi et al., RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through 
R-SPONDIN1. STEMCR. 5, 31–44 (2015). 
70. T. Stein, N. Salomonis, D. S. A. Nuyten, M. J. van de Vijver, B. A. Gusterson, A mouse 
mammary gland involution mRNA signature identifies biological pathways potentially 
associated with breast cancer metastasis. J Mammary Gland Biol Neoplasia. 14, 99–116 
(2009). 
71. T. Stuart et al., Comprehensive Integration of Single-Cell Data. Cell. 177, 1888–1902.e21 
(2019). 
72. C. S. McGinnis, L. M. Murrow, Z. J. Gartner, DoubletFinder: Doublet Detection in Single-Cell 
RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 8, 329–337.e4 (2019). 
73. C. Hafemeister, R. Satija, Normalization and variance stabilization of single-cell RNA-seq 
data using regularized negative binomial regression. Genome Biol. 20, 296–15 (2019). 
74. N. Barkas et al., Joint analysis of heterogeneous single-cell RNA-seq dataset collections. Nat 
Meth. 16, 695–698 (2019). 
75. A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic 
data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 
(2018). 
76. A. L. Haber et al., A single-cell survey of the small intestinal epithelium. Nature Publishing 
Group. 551, 333–339 (2017). 
77. Y. Cao et al., scDC: single cell differential composition analysis. BMC Bioinformatics. 20, 
721–12 (2019). 
78. H. D. J. O. O. S. Software, 2018, Philentropy: information theory and distance quantification 
with R. joss.theoj.org. 
79. D. Kotliar et al., Identifying gene expression programs of cell-type identity and cellular activity 
with single-cell RNA-Seq. eLife. 8, 507 (2019). 
80. G. Korotkevich, V. Sukhov, A. Sergushichev, Fast gene set enrichment analysis. bioRxiv. 10, 
060012 (2019). 
81. D. Legland, I. Arganda-Carreras, P. Andrey, MorphoLibJ: integrated library and plugins for 
mathematical morphology with ImageJ. Bioinformatics. 32, 3532–3534 (2016). 
82. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and  dispersion for 
RNA-seq data with DESeq2. Genome Biol. 15, 550–21 (2014). 
83. Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B 
(Methodological). 57, 289–300 (1995). 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted October 21, 2020. ; https://doi.org/10.1101/430611doi: bioRxiv preprint 
	
	
Fig. 1. Sample-to-sample variability in epithelial cell proportions and transcriptional cell state in 
the human breast. (A) scRNAseq workflow: Reduction mammoplasty samples were processed to a 
single cell suspension, followed by MULTI-seq sample barcoding, FACS purification, and library 
preparation. (B) UMAP dimensionality reduction and unsupervised clustering of the combined data from 
twenty-eight samples identifies the major epithelial and stromal cell types in the breast. (C) Stacked bar 
plot of the proportion of epithelial cells (HR+ luminal; secretory luminal; basal/myoepithelial) across breast 
tissue samples. (D) Density plots highlighting the transcriptional cell state of HR+ luminal cells from 
individuals with at least 100 cells in this cluster. 
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Fig. 2. Prior history of pregnancy is associated with an increased proportion of basal cells in the 
mammary epithelium. (A) UMAP plot of sorted live singlet and epithelial cells from nulliparous and 
parous samples, with the percent of luminal and basal/myoepithelial cells highlighted. (B) Representative 
FACS analysis of the percentage of EpCAM–/CD49f+ basal cells within the Lin– epithelial population, and 
quantification of the percentage of basal cells in parous (P) versus nulliparous (NP) women (n = 18 
samples; p < 0.0001, Mann-Whitney test). (C) Immunostaining for the basal/myoepithelial marker p63 
and pan-luminal marker KRT7, and quantification of the ratio of p63+ basal cells to KRT7+ luminal cells 
for samples with or without prior history of pregnancy (NP = nulliparous, P = parous; n = 13 samples; p 
< 0.001, Mann-Whitney test). Scale bars 50 µm. (D) Two-dimensional geometric model of the relative 
space available for basal cells (outer perimeter of the luminal layer, P) and luminal cells (area of the 
luminal layer, A) within individual acini. Acini were modeled as hollow circles with a shell thickness 
proportional to their diameter. (E) Quantification of the average basal cell coverage (nuclei per μm of 
luminal perimeter) in terminal ductal lobular units (TDLUs) from nulliparous (NP) versus parous (P) 
samples (p = 0.66, Mann-Whitney test). (F) Results of geometric modeling depicting the relative area and 
perimeter of the luminal layer as a function of acinus diameter. Dots represent measurements of individual 
acini from TDLUs in parous (n=53 acini from 7 samples) or nulliparous (n=29 acini from 7 samples) 
women as indicated (mean absolute percentage error = 9.5%). 
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Fig. 3. Obesity is associated with a decrease in the proportion of hormone-responsive cells in the 
luminal compartment. (A) Left: UMAP plot of sorted live singlet and epithelial cells from non-obese (BMI 
< 30) and obese (BMI ≥ 30) samples, highlighting hormone-responsive (HR+) and secretory luminal cells. 
Right: Quantification of the proportion of HR+ or secretory cells in the luminal compartment of obese 
versus non-obese samples (n = 16 samples; FDR < 0.0002, Wald test).  (B) A quasi-Poisson regression 
model accurately predicts the proportion of HR+ cells in the luminal compartment as a function of BMI in 
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an independent cohort of Komen Tissue Bank core biopsy samples (predictive R2 = 0.62, mean absolute 
percentage error = 14.8%; see also fig. S6B and methods). (C) Left: UMAP depicting expression of 
KRT23 in log counts. Right: Dot plot depicting the log normalized mean and frequency of KRT23, ESR1, 
and PGR expression across luminal cell types. (D) Co-immunostaining of PR, KRT23, and the pan-
luminal marker KRT7 and quantification of the percentage of PR+ cells within the KRT7+/KRT23- and 
KRT7+/KRT23+ luminal cell populations (n = 16 samples; p < 0.001 Mann-Whitney test). (E) Co-
immunostaining of KRT23 and KRT7 and linear regression analysis of the percentage of KRT23+ luminal 
cells versus BMI (n = 10 samples; R2 =0.71, p < 0.003, Wald test). Scale bars 50 µm. (F) Summary of 
changes in epithelial cell proportions with pregnancy and obesity: parity is associated with an increase in 
the proportion of basal cells and corresponding decrease in the proportion of luminal cells, whereas 
obesity is associated with a decrease in the proportion of HR+ cells in the luminal compartment. 
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Fig. 4. Hormone signaling is a primary axis of transcriptional variability in HR+ luminal cells. (A) 
PCA plot of HR+ luminal cells depicting expression of WNT4 and TNFSF11 (RANKL) in log counts. (B) 
Non-negative matrix factorization identifies a specific gene signature of hormone signaling in HR+ luminal 
cells. Heatmap depicting the top 20 genes expressed in each HR+ cell metagene, highlighting marker 
genes in HR+ metagene 8. (C) Gene set enrichment analysis of HR+ cell metagene 8, showing 
enrichment of genes shown to be upregulated during the luteal phase of the menstrual cycle (29) (NES 
= 2.16, p < 1e-9). (D) Ridge plots depicting the distribution of HR+ metagene 8 (hormone signaling) 
expression across samples, and quantification of the average expression of metagene 8 in nulliparous 
(NP) versus parous (P) samples (n = 22 samples, p = 0.04, Mann-Whitney test). (E) Immunostaining for 
p63, TCF7, and KRT7, and quantification of the percentage of TCF7+ cells within the p63+ basal cell 
compartment for nulliparous (NP) versus parous (P) samples (n=15 samples; p < 0.002, Mann-Whitney 
test). 
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Fig. 5. Identification of coordinated changes in signaling states across cell types in the breast. 
(A) Left: Network graph of correlated gene expression programs in the human breast. Nodes represent 
distinct metagenes in the indicated cell types, and edges connect highly correlated metagenes (Pearson 
correlation coefficient > 0.5; p < 0.05). Modules of highly correlated gene expression programs were 
identified using the infomap community detection algorithm. The “hormone signaling” metagene in HR+ 
cells (HR+ metagene 8) is highlighted in red. Right: Heatmap depicting Pearson correlation coefficients 
between metagenes in the three major modules (Resting state, Paracrine signaling, Involution). (B) 
Linear regression analysis of basal cell state across metagene 10 (paracrine response) versus HR+ 
luminal cell state across metagene 8 (hormone signaling) (R2 = 0.57, p < 3e-6, Wald test). Dots represent 
the average expression of each metagene within a sample, colored by the proportion of HR+ luminal cells 
in the epithelium for that sample. (C) Summary of multiple linear regression analysis with three predictors: 
HR+ cell hormone signaling (HR+ metagene 8), the frequency of HR+ cells in the epithelium, and an 
interaction term representing the combined effects of HR+ signaling and frequency (Signaling × 
Frequency). (D) Ridge plots depicting the distribution of basal cell metagene 10 (paracrine response) 
expression across samples, and quantification of the average expression in obese (BMI > 30) versus 
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non-obese (BMI ≤ 30) samples (n = 16 samples, p < 0.003, Mann-Whitney test). (E) Schematic depicting 
how parity and obesity lead to decreased hormone signaling in the breast through distinct mechanisms. 
Parity directly affects the per-cell hormone response in HR+ luminal cells, whereas BMI leads to a 
reduction in the proportion of HR+ luminal cells in the epithelium. 
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Materials and Methods 
Tissue samples and preparation 
Reduction mammoplasty tissue samples were obtained from the Cooperative Human Tissue Network 
(CHTN, Vanderbilt University Medical Center, Nashville, TN) and Kaiser Permanente Northern California 
(KPNC, Oakland, CA). Core biopsy samples were provided by the Susan G. Komen Tissue Bank (KTB). 
Tissues were obtained as de-identified samples and all subjects provided written informed consent. When 
possible, medical reports or other patient data were obtained with personally identifiable information 
redacted. Use of breast tissue specimens to conduct the studies described above were approved by the 
UCSF Committee on Human Research under Institutional Review Board protocols 16-18865 and 10-
01532. A portion of each sample was fixed in formalin and paraffin-embedded using standard procedures. 
The remainder was dissociated mechanically and enzymatically to obtain epithelial-enriched tissue 
fragments. Tissue was minced, followed by enzymatic dissociation with 200 U/mL collagenase type III 
(Worthington CLS-3) and 100 U/mL hyaluronidase (Sigma H3506) in RPMI 1640 with HEPES (Corning 
10-041-CV) plus 10% (v/v) dialyzed FBS, penicillin, streptomycin, amphotericin B (Lonza 17-836E), and 
gentamicin (Lonza 17-518) at 37 °C for 16 h. For KTB samples, the cell suspension containing single 
cells and stroma was frozen and maintained at -180 °C until use. For reduction mammoplasty samples, 
the cell suspension was centrifuged at 400 x g for 10 min and resuspended in RPMI 1640 plus 10% FBS. 
Digested tissue fragments enriched for epithelial cells and associated stroma were collected after serial 
filtration through 150 µm and 40 µm nylon mesh strainers. Following centrifugation, tissue fragments and 
filtrate were frozen and maintained at -180 °C until use. 
 
Dissociation to single cells 
The day of sorting, epithelial-enriched tissue fragments from the 150 µm fraction, or total banked material 
for the KTB samples, were thawed and digested to single cells by trituration in 0.05% trypsin for 2 min, 
followed by trituration in 5 U/mL dispase (Stem Cell Technologies 07913) plus 1 mg/mL DNase I (Stem 
Cell Technologies 07900) for 2 min. Single-cell suspensions were resuspended in HBSS supplemented 
with 2% FBS, filtered through a 40 µm cell strainer, and pelleted at 400 x g for 5 min. The pellets were 
resuspended in 10 mL of complete mammary epithelial growth medium with 2% v/v FBS without GA-
1000 (MEGM; Lonza CC-3150). Cells were incubated at 37 °C for 1 h, rotating on a hula mixer, to 
regenerate surface antigens.  
 
MULTI-seq sample barcoding 
Single-cell suspensions were pelleted at 400 x g for 5 min and washed once with 10 mL mammary 
epithelial basal medium (MEBM; Lonza CC-3151). For each sample, one million cells were aliquoted, 
washed a second time with 200 μL MEBM, and resuspended in 90 μL of a 200 nM solution containing 
equimolar amounts of anchor lipid-modified oligonucleotides (LMOs) and sample barcode 
oligonucleotides in phosphate buffered saline (PBS). Following a 5-minute incubation on ice with anchor-
LMO/barcode, 10 uL of 2 μM co-anchor LMO in PBS was added to each sample (for a final concentration 
of 200 nM), and wells were mixed by gentle pipetting and incubated for an additional 5 min on ice. 
Following incubation, cells were washed twice in 200 μL PBS with 1% BSA and pooled together into a 
single 15 mL conical tube containing 10 mL PBS/1% BSA. All subsequent steps were performed on ice. 
 
Sorting for scRNA-seq 
Cells were pelleted at 400 x g for 5 min and resuspended in PBS/1% BSA at a concentration of 1 million 
cells per 100 μL, and incubated with primary antibodies. Cells were stained with Alexa 488-conjugated 
anti-CD49f to isolate basal/myoepithelial cells, PE-conjugated anti-EpCAM to isolate luminal epithelial 
cells, and biotinylated antibodies for lineage markers CD2, CD3, CD16, CD64, CD31, and CD45 to 
remove hematopoietic (CD16/CD64-positive), endothelial (CD31-positive), and leukocytic 
(CD2/CD3/CD45-positive) lineage cells by negative selection (Lin-). Sequential incubation with primary 
antibodies was performed for 30 min on ice in PBS/1% BSA, and cells were washed with cold PBS/1% 
BSA. Biotinylated primary antibodies were detected with a streptavidin-Brilliant Violet 785 conjugate. After 
incubation, cells were washed once and resuspended in PBS/1% BSA plus 1 ug/mL DAPI for live/dead 
discrimination. Cell sorting was performed on a FACSAria II cell sorter. Live singlet (DAPI-), luminal 
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(DAPI-/Lin-/CD49f-/EpCAMhigh), myoepithelial (DAPI-/Lin-/CD49f+/EpCAMlow), or total epithelial 
(pooled luminal and myoepithelial) cells were collected for each sample as specified in table S2 and 
resuspended in PBS/1% BSA at a concentration of 1000 cells/µL. For Batch 4, an aliquot of MULTI-seq 
barcoded cells were separately stained with biotinylated-CD45/streptavidin-Brilliant Violet 785 to enrich 
for immune cells, and sorted CD45+ cells were pooled with the Live/singlet fraction as specified in table 
S2. 
 
Antibodies and dilutions used (µL/million cells) were as follows: FITC-EpCAM (1.5 µL; BD 550257, clone 
AD2), APC-CD49f (4 µL; Stem Cell Technologies 10109, clone VU1D9), Biotin-CD2 (8 µL; Biolegend 
313636, clone GoH3), Biotin-CD3 (8 µL; BD 55325, clone RPA-2.10), Biotin-CD16 (8 µL; BD 55338, 
clone HIT3a), Biotin-CD64 (8 µL; BD 555526, clone 10.1), Biotin-CD31 (4 µL; Invitrogen MHCD31154, 
clone MBC78.2), Biotin-CD45 (1 µL; Biolegend 304004, clone HI30), BV785-Streptavidin (1 µL; 
Biolegend 405249). 
 
scRNAseq library preparation 
cDNA libraries were prepared using the 10X Genomics Single Cell V2 (CG00052 Single Cell 3’ Reagent 
Kit v2: User Guide Rev B) or Single Cell V3 (CG000183 Single Cell 3’ Reagent Kit v3: User Guide Rev 
B) standard workflows as specified in table S2. Library concentrations were quantified using high 
sensitivity DNA Bioanalyzer chips (Agilent, 5067-4626), the Illumina Library Quantification Kit (Kapa 
Biosystems KK4824), and Qubit dsDNA HS Assay Kit (Thermo Fisher Q32851). Individual libraries were 
separately sequenced on a lane of a HiSeq4500 or NovaSeq, as specified in table S2, for an average of 
~150,000 reads/cell. 
 
Expression library pre-processing 
Cell Ranger (10x Genomics) was used to align sequences, filter data and count unique molecular 
identifiers (UMIs). Data were mapped to the human reference genome GRCh37 (hg19). The resulting 
sequencing statistics are summarized in table S2. For each experimental batch, the cellranger aggr 
pipeline (10X Genomics) was used to normalize read depth across droplet microfluidic lanes. 
 
Cell calling 
For V2 experiments, cell-associated barcodes were defined using Cell Ranger. For V3/MULTI-seq 
experiments, cells were defined as barcodes associated with ≥600 total RNA UMIs and ≤20% of reads 
mapping to mitochondrial genes. We manually selected 600 RNA UMIs and 20% mitochondrial genes to 
exclude low-quality cell barcodes. 
 
MULTI-seq barcode library pre-processing 
Raw barcode FASTQs were converted to barcode UMI count matrices as described previously (16). 
Briefly, FASTQs were parsed to discard reads where: 1) the first 16 bases of read 1 did not match a list 
of cell barcodes generated as described above, and 2) the first 8 bases of read 2 did not align with any 
reference barcode with less than 1 mismatch. Duplicated UMIs, defined as reads with the same cell 
barcode where bases 17-26 (V2 chemistry) or bases 17-28 (V3 chemistry) of read 2 exactly matched, 
were removed to produce a final barcode UMI count matrix. 
 
Sample demultiplexing 
Barcode UMI count matrices were used to classify cells using the MULTI-seq classification suite (16). In 
Batch 3, sample RM192 was poorly labeled for the lane of cells from the epithelial cell sort gate. 
Therefore, to reduce spurious doublet calls in this dataset, we manually set UMI counts which were <10 
for this barcode to zero. For all experiments, raw barcode reads were log2-transformed and mean-
centered, the top and bottom 0.1% of values for each barcode were excluded, and a probability density 
function (PDF) was constructed for each barcode. Next, all local maxima were computed for each PDF, 
and the negative and positive maxima were selected. To define a threshold between these two maxima, 
we iterated across 0.02-quantile increments and chose the quantile maximizing the number of singlet 
classifications, defined as cells surpassing the threshold for a single barcode. Multiplets were defined as 
cells surpassing two or more thresholds, and unlabeled cells were defined as cells surpassing zero 
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thresholds. Unclassified cells were removed and the procedure was repeated until all remaining cells 
were classified.  
 
To classify cells that were identified as unlabeled by MULTI-seq, we used the souporcell pipeline (15) to 
assign cells to different individuals based on single nucleotide polymorphisms (SNPs). For each dataset, 
we set the number of clusters (k) to the total number of samples in that experiment. To avoid local minima, 
souporcell restarts clustering multiple times and takes the solution that minimizes the loss function. For 
Batch 3, we chose the number of restarts that produced less than a 1.5% misclassification rate between 
MULTI-seq and souporcell singlet sample classifications (Live singlet: 30 restarts/1.2% mismatch rate; 
Epithelial: 75 restarts/1.5% mismatch rate). Souporcell classification performed more poorly across 
parameters for Batch 4 (Live singlet plus CD45+: 50 restarts/8.1% mismatch rate, 75 restarts/4.8% 
mismatch rate; Epithelial: 50 restarts/8.6% mismatch rate, 75 restarts/14.9% mismatch rate, 100 
restarts/4.1% mismatch rate). Therefore, for these datasets we used sample classifications that were 
consistent across two restarts (Pooled live singlet/ CD45+: consistent calls across 50 and 75 
restarts/0.4% overall mismatch rate; Epithelial: consistent calls across 50 and 100 restarts/1% overall 
mismatch rate) to identify high-confidence singlets.  
 
Quality control, dataset integration, and cell type identification using Seurat 
Cell type identification was performed using the Seurat package (version 3.0.0) in R (71). To identify 
doublets from the same sample that would not be identified by MULTI-seq or souporcell, we filtered each 
lane to remove cells with greater than 20% of reads mapping to mitochondrial genes and ran 
DoubletFinder (version 2.0) on each data subset (72), using parameters identified by the 
‘paramSweep_v3’ function. Aggregated data for singlet cells for each batch was filtered to remove cells 
that had fewer than 200 genes and genes that appeared in fewer than 3 cells. Cells with a Z score of 4 
or greater for the total number of genes expressed were presumed to be doublets and removed from 
analysis. The remaining cells were log transformed and scaled to a total of 1e4 molecules per cell, and 
the top 2000 most variable genes based on variance stabilizing transformation were identified for each 
batch (73). Data from all four batches were integrated using the standard workflow and default 
parameters from Seurat v3 (71). This data integration workflow identifies pairwise correspondences 
between cells across datasets and uses these anchors to transform datasets into a shared expression 
space. Following dataset integration, the resulting batch-corrected expression matrix was scaled, and 
principal component (PC) analysis was performed using the identified integration genes. The top 28 
statistically significant PCs as determined by visual inspection of elbow plots were used as an input for 
UMAP visualization and k-nearest neighbor (KNN) modularity optimization-based clustering using 
Seurat’s FindNeighbors and FindClusters functions.  
 
Quantification of sample-to-sample heterogeneity 
To measure how well-mixed cells from different samples were across cell type clusters, we quantified the 
normalized relative entropy for our dataset, weighted by cluster size (74). A cluster entropy value of 1 
represents complete intermixing of samples across clusters. To measure transcriptional variation in cell 
state within cell types between cells from the same versus different batches and/or samples, we 
measured the pairwise “alignment score” between each sample/batch (75), where batches consisted of 
sets of samples processed on the same day (table S2). This metric examines the local neighborhood of 
each cell in a particular sample/batch, asks how many of its k nearest neighbors belong to a second 
sample/batch, and averages this over all cells. The result was normalized by the expected number of 
cells from each sample/batch. Notably, for repeat measurements, samples run across multiple batches 
were highly similar. 
 
Testing for changes in cell type proportions and predictive modeling 
We modeled the detected number of each cell type in each sample as a random count variable using a 
quasi-Poisson process to allow for overdispersion, with the condition being tested (e.g. parity, obesity) 
as a predictor and the total number of detected epithelial or luminal cells in each sample as an offset 
variable (76). To account for uncertainty due to variable numbers of profiled cells in each sample, we 
used bootstrap resampling to estimate confidence intervals associated with detection of each cell type 
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(77). Results from 1000 bootstrap replicates were pooled using the mice::pool function in R, and the 
model was fit using a quasi-Poisson generalized linear model from the ‘stats’ R package. Tests for 
statistical significance were performed using a Wald test on the regression coefficient. Multiple hypothesis 
correction was controlled using the false discovery rate. For the Komen Tissue Bank (KTB) data set, a 
quasi-Poisson model was trained on the reduction mammoplasty cohort as described above, and the 
‘predict’ function in the ‘stats’ R package was used to predict the proportion of HR+ luminal cells in the 
KTB samples based on BMI. 
 
PC analysis within HR+ luminal cells 
To perform principal component analysis on HR+ luminal cells, we subset out this cluster from the 
integrated dataset and repeated the standard workflow from Seurat v3 to identify integration genes 
specific to this cell type. The resulting batch-corrected expression matrices were scaled, and PC analysis 
was performed using the identified integration genes.  
 
Non-negative matrix factorization of individual cell types 
To identify gene expression signatures, or “metagenes” within individual cell types, we subset out raw 
counts data from each of the four most abundant clusters (HR+ luminal cells, secretory luminal cells, 
basal cells, and fibroblasts) and performed matrix factorization. We chose to perform matrix factorization 
independently on each cell type rather than on the combined dataset, as preliminary analyses 
demonstrated that the number of metagenes identified for each cell type was highly dependent on the 
relative sizes of each cluster in the combined dataset. To account for batch differences, we used the 
LIGER package in R to perform integrative NMF {Welch:2019dz, Yang:2016fu}, and performed all 
subsequent analyses on shared, rather than batch-specific, metagenes. To avoid identification of gene 
signatures dominated by highly-expressed transcripts, we normalized the raw counts matrix for each cell 
based on its total expression, multiplied by a scale factor of 1e4, and log-transformed and scaled the 
result without centering. The resulting dataset was decomposed using the standard workflow and default 
parameters from LIGER. To estimate the optimum choice of rank K (i.e. number of NMF components) for 
each cell type, we used the suggestK function in the LIGER package to calculate the Kullback-Leibler 
(KL) divergence of metagene loadings across a range of K values, and identified the elbow point on this 
curve. 
 
Jensen-Shannon distance to quantify sample-to-sample variability in hormone signaling 
To quantify variation in expression of the “hormone signaling” metagene in HR+ luminal cells (HR+ 
metagene 8), we performed the following workflow. First, we used the cell loadings across HR+ metagene 
8 for each sample to compute kernel density estimations using the ‘density’ function in the ‘stats’ R 
package. Second, we used the ‘JSD’ function in the ‘philentropy’ R package (78) to measure the pairwise 
Jensen-Shannon divergence between samples. Third, we converted this to a distance metric (Jensen-
Shannon Distance, JSD) by taking the square root and performed hierarchical clustering using the ‘hclust’ 
function in the ‘stats’ R package, using ‘ward.D2’ linkage. The similarity between samples was plotted on 
a heatmap as (1-JSD).  
 
Metagene network analysis 
To identify sets of gene expression programs that co-varied across samples, we first decomposed each 
cell type into a set of distinct gene expression programs, or “metagenes”, using NMF as described above. 
We then quantified the average expression of each metagene in each sample and constructed a weighted 
network of coordinated gene expression programs based on the pair-wise Pearson correlations between 
metagenes. To account for correlations driven by outlier samples, we used bootstrap resampling to 
estimate confidence intervals associated with each correlation coefficient. The resulting Pearson 
correlation matrix was transformed into a weighted adjacency matrix by setting all Pearson correlation 
coefficients less than 0.5 or with p-values less than 0.05 to zero. Finally, we identified modules of highly 
correlated gene expression programs using the infomap community detection algorithm in the ‘igraph’ 
package in R (43). We chose this flow-based community detection algorithm in order to maximize 
information flow within clusters. Results using the modularity-based Louvain clustering algorithm were 
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identical except that a small community consisting of three metagenes was merged with the “involution” 
module. 
 
Gene set enrichment analysis 
To identify marker genes statistically associated with each metagene, we used multiple least squares 
regression of normalized (z-scored) gene expression against the cell loading matrix for each metagene 
(79). This results in a vector of regression coefficients representing the strength of the relationship 
between expression of a particular metagene and scaled expression of each gene. The resulting ranked 
gene lists were analyzed by gene set enrichment analysis, using the ‘fgsea’ package in R (80).  
 
Fluorescent Immunohistochemistry 
For immunofluorescent staining, formalin-fixed paraffin-embedded tissue sections were deparaffinized 
and rehydrated using standard methods. Endogenous peroxides were blocked using 3% hydrogen 
peroxide in PBS, and antigen retrieval was performed in 0.1 M citrate buffer pH 6.0. Sections were 
blocked for 5 min at room temperature using Lab Vision Ultra-V block (Thermo TA-125-UB) and rinsed 
with TNT wash buffer (1X Tris-buffered saline with 5 mM Tris-HCl and 0.5% TWEEN-20). Primary 
antibody incubations were performed for 1 hour at room temperature or overnight at 4°C. Sections were 
washed three times for 5 min each with TNT wash buffer, incubated with Lab Vision UltraVision LP 
Detection System HRP Polymer (Thermo Fisher TL-060-HL) for 15 min at room temperature, washed, 
and incubated with one of three colors of TSA amplification reagent at a 1:50 dilution. After tyramide 
signal amplification, antibody complexes were removed by boiling in citrate buffer, followed by blocking 
and incubation with additional primary antibodies as above. Finally, sections were rinsed with deionized 
water and mounted using Vectashield HardSet Mounting Media with DAPI (Vector H-1400). 
Immunofluorescence was analyzed by spinning disk confocal microscopy using a Zeiss Cell Observer 
Z1 equipped with a Yokagawa spinning disk and running Zeiss Zen Software. 
 
Antibodies, TSA reagents, and dilutions used are as follows: p63 (1:2000; CST 13109, clone D2K8X), 
KRT7 (1:4000; Abcam AB68459, clone EPR1619Y), KRT23 (1:2000; Abcam AB156569, clone 
EPR10943), ER (1:4000; Thermo Scientific RMM-9101-S, clone SP1), PR (1:3000; CST 8757, clone 
D8Q2J), TCF7 (1:2000; CST 2203, clone C63D9), FITC-TSA (2 min; Perkin Elmer NEL701A001KT), 
Cy3-TSA (3 min; Perkin Elmer NEL744001KT), Cy5-TSA (7 min; Perkin Elmer NEL745E001KT). 
 
Morphometric analysis and geometric modeling 
Formalin-fixed paraffin-embedded tissue sections were immunostained for the pan-luminal marker KRT7, 
counterstained with DAPI and imaged as described above. Images containing lobular tissue were 
acquired randomly, and the area and perimeter of the KRT7-positive luminal layer of each acinus was 
analyzed in ImageJ. To reduce noise and remove small gaps in KRT7 fluorescence, we applied a closing 
filter from the MorphoLibJ plugin with a 2-pixel (1.33 μm) radius disk (81). The resulting image was 
smoothed by applying a Gaussian filter with sigma 5 pixels (3.33 μm), and binarized using the default 
thresholding algorithm in ImageJ. Finally, individual acini with visible lumens were manually selected and 
the area (A), perimeter (P), and circularity of the KRT7-positive region was measured for each structure. 
To estimate the average diameter (d) and luminal thickness (w) of each acinus, we used area and 
perimeter measurements to fit a circle containing a hollow lumen to each structure. Based on these 
results, we implemented a geometric model in which each acinus was represented as a hollow circle with 
shell thickness that was linearly related to diameter (d). To estimate the linear relationship between w 
and d, we performed linear regression analysis using measurements from all structures with a circularity 
greater than 0.75 (n = 55 acini from 15 samples).  
 
Pseudo-bulk differential gene expression analysis 
To identify genes differentially expressed between samples from parous and nulliparous or obese and 
non-obese individuals in specific cell types, we constructed pseudo-bulk datasets consisting of the 
summed raw read counts across all single HR+ luminal cells or basal cells for each batch and sample. 
We restricted our analysis to samples/batches that had at least 100 cells of the cell type of interest. Each 
dataset was then randomly down-sampled to the lowest library size, and differential expression analysis 
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was performed using DESeq2 (version 1.18.1) to test for genes differentially expressed between samples 
from obese (BMI ≥ 30) and non-obese (BMI < 30) or parous and nulliparous individuals, using batch as 
a covariate (82). As certain samples were sequenced across more than one batch (table S2), replicates 
of the same sample from different batches were combined using the collapseReplicates function. False 
discovery rate corrected p-values were calculated using the Benjamini-Hochberg procedure (83). 
 
RNA FISH analysis of ESR1 transcripts 
Combined RNA FISH and immunofluorescence analysis of estrogen receptor transcript (RNAscope 
Probe Hs-ESR1; ACD 310301) and protein (anti-ER; Thermo RMM-9101-S, clone SP1) was performed 
using the RNAscope in situ hybridization kit (RNAscope Multiplex Fluorescent Reagent Kit V2, ACD 
323100) according to the manufacturer’s instructions and fluorescent immunohistochemistry protocol 
outlined above with the following modifications. Immunostaining for ER was performed prior to in situ 
hybridization, using the hydrogen peroxide and antigen retrieval solutions supplied with the RNAscope 
kit and the mildest recommended conditions. After ER immunostaining and tyramide signal amplification, 
in situ hybridization for ESR1 was performed according to the manufacturer’s instructions, followed by 
immunostaining for KRT7 as described above. For all RNA FISH experiments, we used positive (PPIB) 
and negative controls (DAPB) to verify staining conditions and probe specificity. 
 
Data and code availability 
Submission of raw gene expression and barcode count matrices to the Gene Expression Omnibus is in 
process. For inquiries contact authors.  
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Fig. S1. Sorting strategy and MULTI-seq barcoding for scRNAseq experiments.  
(A) FACS plots depicting sort gates used for sequencing. (B) TSNE dimensionality reduction of the 
normalized barcode count matrices and final sample classification for MULTI-seq experiments (Batches 
3 and 4). (C) UMAP dimensionality reduction of the combined data from twenty-eight samples for each 
sort population.  
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Fig. S2. Marker analysis of cell type clusters for scRNAseq experiments. (A) Heatmap highlighting 
marker genes used to identify each cell type. For visualization purposes, we randomly selected 100 
cells from each cluster. (B) UMAPs depicting expression of selected markers in log counts. (C) Dot plot 
depicting the log normalized mean and frequency of ESR1 and PGR expression across cell type 
clusters. (D) Venn diagram highlighting the frequency of ESR1 and PGR expression and percent 
overlap in the HR+ luminal cell cluster.	
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Fig. S3. Two sources of inter-sample variability in the breast. (A) UMAP for each sample highlighting 
cell types identified by unsupervised clustering. Cells from different individuals are represented across 
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all clusters (cluster entropy = 0.93). (B) Quantification of the proportion of epithelial cells 
(basal/myoepithelial; HR+ luminal; secretory luminal) in each sample, with the cross-sample median and 
range for each cell type (n = 28 samples). (C) Density plots highlighting the transcriptional cell state of 
basal/myoepithelial cells, secretory luminal cells, or fibroblasts from individuals with at least 100 cells in 
each cluster. (D) UMAP of samples that were run across multiple batches, highlighting cells from each 
batch. (E) Quantification of the “mixing metric”—or similarity—between cells from the same or different 
sample and batch for the indicated cell types. See table S2 for sample and batch information. 
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Fig. S4. Prior pregnancy is associated with changes in epithelial cell proportions. (A) Quantification 
of the proportion of basal/myoepithelial cells (Basal), HR+ luminal cells (HR+), and secretory luminal cells 
(Secretory) in the mammary epithelium of nulliparous (NP) versus parous (P) samples, as identified by 
scRNAseq clustering (n = 28 samples; Wald test). (B) Quantification of the percentage of EpCAM–
/CD49f
+
 basal cells identified by FACS analysis versus age (n = 23; R
2
 = 0.20; p < 0.04, Wald test), body 
mass index (n = 21; R
2
 = 0.03; p = 0.44, Wald test), race (n = 23; p = 0.55, Mann-Whitney test), or 
hormonal contraceptive use (n = 23; p = 0.50, Kruskal-Wallis test). (C) Microarray differential expression 
analysis for selected genes from Santucci-Periera et al. and Peri et al. (20, 21). 
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Fig. S5. Prior pregnancy is associated with changes in epithelial architecture. (A) Immunostaining 
for the basal/myoepithelial marker p63 and pan-luminal marker KRT7, and quantification of the ratio of 
p63+ myoepithelial cells to KRT7+ luminal cells in the ducts and terminal ductal lobular units (TDLUs) for 
parous (P) versus nulliparous (NP) samples (n = 14 samples; Mann-Whitney test). Scale bars 50 µm. (B) 
Quantification of the average acinar diameter in TDLUs from nulliparous (NP) versus parous (P) samples 
(n = 14 samples; p < 0.002, Mann-Whitney test). (C) Linear regression analysis of the width of the luminal 
layer versus acinus diameter for individual acini with circularity greater than 0.75 (n = 56 acini from 15 
samples; R
2
 = 0.89, p < 0.0001, Wald test). (D) Quantification of the average thickness of the luminal 
layer in TDLUs of nulliparous (N) versus parous (P) samples (n = 14 samples; p < 0.002, Mann-Whitney 
test). (E) Quantification of the average luminal cell density (nuclei per μm2 of luminal area) in TDLUs from 
nulliparous (NP) versus parous (P) samples (p = 0.43, Mann-Whitney test). (F) Left: Linear regression 
analysis of the perimeter of the luminal layer versus the number of p63+ basal cells for individual acini (n 
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= 72 acini from 13 samples; R
2
 = 0.55, p < 0.0001, Wald test). Right: Linear regression analysis of the 
area of the luminal layer versus the number of KRT7+ luminal cells for individual acini (n = 72 acini from 
13 samples; R
2
 = 0.81, p < 0.0001, Wald test). 
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Fig. S6. The proportion of HR+ luminal cells is reduced in obese women and does not vary with 
other discriminating factors. (A) Proportion of HR+ luminal cells in each sample (dots) stratified by 
age, reproductive history, hormonal contraceptive use, or race (p > 0.05, Wald test). (B) Quasi-Poisson 
regression model of the proportion of HR+ cells in the luminal compartment as a function of BMI (FDR < 
0.001, Wald test). (C) UMAP plot of sorted luminal cells from non-obese (BMI < 30) and obese (BMI > 
30) samples, highlighting hormone-responsive (HR+) and secretory luminal cells. 
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Fig. S7. Summary of scRNAseq analysis of samples from the Komen Tissue Bank. (A) Scatter plots 
highlighting differences in body mass index (BMI), reproductive history, and average age between the 
Komen Tissue Bank (KTB) and reduction mammoplasty cohorts (see also table S1). Trendline depicts 
the positive association of BMI with Age in the reduction mammoplasty cohort. (B) TSNE dimensionality 
reduction of the normalized barcode count matrices and final sample classification for MULTI-seq 
Macrophage
Lymphocyte
Vascular accessory
KTB038
KTB067
Excluded 
from analysis
(< 100 cells)
Unlabeled
Doublet
Nulliparous Parous Parous
20
30
40
50
BM
I
Reduction
mammoplasty
Komen
bank
20 30 40 50
Age
Reduction 
mammoplasty
Komen bank
A B
MULTI-seq Classification:
KTB006
KTB001
KTB010
KTB018
KTB025
KTB042
KTB052
TSNE 1
TS
NE
 2
UMAP 1
UM
AP
 2
Basal/myoepithelial
Fibroblast
Secretory luminal
HR+ luminal
Endothelial
C
6
7
8
1
2
3
4
5
D ANKRD30A SLPIUMAP 1
UM
AP
 2
Log
expression
0
2
IL1B
IDO1
FCER1G
CD163
CCL4
CCL3
MS4A1
IGJ
CD8A
CD79A
CD7
CD69
RGS5
PLN
KCNE4
GJA4
ENPEP
CPM
PLVAP
ENG
FABP4
ECSCR
CLDN5
CDH5
ANGPT2
ESAM
PDPN
PDGFRA
MMP2
IGFBP6
FN1
DCN
COL1A1
SLPI
PROM1
LTF
KRT15
KIT
GABRP
BBOX1
ALDH1A3
TFF3
TFF1
PIP
AREG
AR
ANKRD30A
ALCAM
AGR2
MUC1
KRT8
KRT19
KRT18
EPCAM
ELF3
TAGLN
SFN
MYLK
MYL9
KRT5
KRT17
KRT14
ACTG2
ACTA2
C1
Basal/
myoepithelial
C7
Lymphocyte
C6
Vascular
Accessory
C5
Endothelial
C4
Fibroblast
C3
Secretory
luminal
C2
HR+
luminal
C8
Macrophage
E Row
z-score
-2
2
Random sample of 50 cells per cluster
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was notthis version posted October 21, 2020. ; https://doi.org/10.1101/430611doi: bioRxiv preprint 
barcoding. (C) UMAP dimensionality reduction and unsupervised clustering of the combined data from 
seven KTB samples identifies the major epithelial and stromal cell types in the breast. (D) UMAPs 
depicting expression of selected markers in log counts. (E) Heatmap highlighting marker genes used to 
identify each cell type. For visualization purposes, we randomly selected 50 cells from each cluster. 
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Fig. S8. Hormone receptor expression is highly variable. (A) Top: Co-immunostaining of PR and 
KRT7 and linear regression analysis of the percentage of PR+ luminal cells versus BMI (n = 10 samples; 
R
2
 =0.29, p = 0.11, Wald test). Bottom: Co-immunostaining of ER and KRT7 and linear regression 
analysis of the percentage of ER+ luminal cells versus BMI (n = 8 samples; R
2
 =0.06, p = 0.56, Wald 
test). Scale bars 50 µm. (B) Venn diagram highlighting the average percent overlap between ER and PR 
as measured by immunostaining (n = 5 samples, range = 11-71%). (C) Multiplexed in situ hybridization 
of estrogen receptor transcript (ESR1) and immunostaining for estrogen receptor protein (ER) and KRT7. 
Right: Plots depicting the expression of ESR1 and ER across multiple tissue sections (R2 = 0.6, p < 0.01, 
Wald test) or within individual cells (p = 0.63, Wilcoxon matched pairs signed-rank test). Scale bars 25 
µm. (D) Table and bar plot depicting the sensitivity and specificity for ESR1 or PGR transcript expression 
in the HR+ luminal cell versus secretory luminal cell cluster.  
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Fig. S9. Keratin 23 is a specific marker of cells in the secretory luminal cell lineage. (A) 
Representative images of co-immunostaining of PR, KRT23, and the pan-luminal marker KRT7. (B) Co-
immunostaining of ER, KRT23, and the pan-luminal marker KRT7 and quantification of the percentage 
of ER+ cells within the KRT7+/KRT23- and KRT7+/KRT23+ luminal cell populations (n = 5 samples; p < 
0.01 Mann-Whitney test). Scale bars = 50 µm. (C) Linear regression analysis of the percentage of luminal 
cells in the secretory lineage identified by scRNAseq clustering versus the percentage of KRT23+ luminal 
cells identified by immunostaining (n = 15 samples; R
2
 =0.71, p < 0.0001, Wald test). 
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Fig. S10. Matrix decomposition analysis of HR+ luminal cells. (A) Heatmap highlighting the 20 genes 
with the highest loadings in PC1, annotated by their association with estrogen signaling, progesterone 
signaling, or the luteal phase of the menstrual cycle. HR+ luminal cells are ordered by their cell loadings 
in PC1. (B) Barchart depicting the proportion of variance explained by each of the top 20 principal 
components. (C) Parameter selection for non-negative matrix factorization based on KL divergence plots 
(methods). (D) Heatmap of cell loadings across each metagene for HR+ luminal cells. (E) PCA plot of 
HR+ luminal cells depicting expression of HR+ metagene 8. (F) Gene set enrichment analysis of HR+ 
cell metagene 8, showing the top pathways identified from the Molecular Signatures Database Hallmark 
and GO gene sets. 
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Fig. S11. Parity is associated with a decrease in the per-cell hormone signaling response of HR+ 
luminal cells. (A) Heatmap showing the similarity between each sample’s single-cell expression 
distribution across HR+ cell metagene 8, measured as (1 - Jensen-Shannon distance). Hierarchical 
clustering identifies two sets of samples representing high or low expression of the “hormone signaling” 
metagene (ward D2). (B) PCA plot of HR+ luminal cells in nulliparous or parous women depicting 
expression of HR+ cell metagene 8. (C) Volcano plot highlighting the differential expression of canonical 
hormone-responsive genes between parous and nulliparous samples in HR+ luminal cells. (D) 
Immunostaining for PR, KRT23, and KRT7, and quantification of the percentage of PR+ cells within the 
KRT23-/KRT7+ luminal cell compartment for nulliparous (NP) versus parous (P) samples (n=15 samples; 
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p < 0.03, Mann-Whitney test). (E) Immunostaining for p63, TCF7, and KRT7 in ducts versus TDLUs, and 
quantification of the percentage of TCF7+ cells within the p63+ basal cell compartment (n = 14 samples; 
p = 0.64, Mann-Whitney test). 
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Fig. S12. Matrix decomposition analysis of secretory luminal cells, basal/myoepithelial cells, and 
fibroblasts. (A) Parameter selection for non-negative matrix factorization based on KL divergence plots 
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(methods). (B) Heatmap of cell loadings across each metagene for the indicated cell types. (C) Left: 
Network graph of coordinated gene expression programs in the human breast. Nodes represent distinct 
metagenes in the indicated cell types, and edges connect highly correlated metagenes (Pearson 
correlation coefficient > 0.5 and p < 0.05). Modules of highly correlated gene expression programs were 
identified using the infomap community detection algorithm. The “hormone signaling” metagene in HR+ 
cells (HR+ metagene 8) is highlighted in red. Right: Heatmap depicting Pearson correlation coefficients 
between all metagenes. 
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Fig. S13. The “Resting state” module consists of metagenes negatively correlated with hormone 
signaling in HR+ luminal cells. (A) Network subgraph of the “resting state” module, and heatmap 
depicting Pearson correlation coefficients between all metagenes and levels of significance (* p < 0.05, 
** p < 0.01, *** p < 0.001). (B) Gene set enrichment analysis for the indicated metagenes, showing the 
top pathways identified from GO gene sets. 
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Fig. S14.  The “Paracrine signaling” module consists of metagenes positively correlated with 
hormone signaling in HR+ luminal cells. (A) Network subgraph of the “paracrine signaling” module, 
and heatmap depicting Pearson correlation coefficients between all metagenes and levels of significance 
(* p < 0.05, ** p < 0.01, *** p < 0.001). Right: Betweenness centrality for each metagene within the 
paracrine signaling module. (B) Left: Linear regression analysis of HR+ cell state across metagene 5 
(“hypoxia”) versus metagene 8 (“hormone signaling”) (R
2
 = 0.37, p < 0.0004, Wald test). Dots represent 
the average expression of each metagene within a sample. Right: Scatter plot of HR+ cell expression of 
metagene 5 versus metagene 8. Dots represent the expression of each metagene within individual HR+ 
luminal cells. (C) Left: Heatmap depicting the top 20 genes expressed in each HR+ cell metagene, 
highlighting metagene 5. Right: Gene set enrichment analysis for HR+ metagene 5, showing the top 
pathways identified from the Molecular Signatures Database Hallmark and GO gene sets. (D) Left: 
Heatmap depicting the top 20 genes expressed in each secretory luminal cell metagene, highlighting 
metagene 8. Right: Gene set enrichment analysis for secretory cell metagene 8, showing the top 
pathways identified from the Molecular Signatures Database Hallmark and GO gene sets. (E) Gene set 
enrichment analysis of secretory luminal cell metagene 8, showing enrichment of genes upregulated 
during the luteal phase of the menstrual cycle (29) (NES = 2.38, p < 2e-30). (F) Left: Heatmap depicting 
the top 20 genes expressed in each basal cell metagene, highlighting metagene 10. Right: Gene set 
enrichment analysis for basal cell metagene 10, showing the top pathways identified from the Molecular 
Signatures Database Hallmark, GO, and Canonical Pathways gene sets. (G) Left: Heatmap depicting the 
top 20 genes expressed in each fibroblast metagene, highlighting metagenes 5 and 7. Right: Gene set 
enrichment analysis for fibroblast metagenes 5 and 7, showing the top pathways identified from the 
Molecular Signatures Database Hallmark and GO gene sets. 
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Fig. S15.  The “Involution” module consists of metagenes enriched for genes upregulated during 
post-lactational involution. (A) Network subgraph of the “involution” module, highlighting the two 
metagenes most closely associated with an “involution-like” gene signature. (B) Heatmap depicting the 
top 20 genes expressed in each HR+ cell or secretory cell metagene, highlighting “involution-like” gene 
signatures. Right: Gene set enrichment analysis of the indicated metagenes, showing enrichment of 
genes upregulated during the postlactational involution (70) (HR+ metagene 3: NES = 1.65, p < 0.008; 
Secretory cell metagene 2: NES = 1.97, p < 2e-6). (C) Gene set enrichment analysis for the indicated 
metagenes, showing the top pathways identified from the Molecular Signatures Database Hallmark and 
GO gene sets. 
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Fig. S16. Paracrine signaling to basal cells depends on the hormone signaling state of HR+ 
luminal cells and the proportion of HR+ luminal cells in the epithelium. (A) Plot depicting the 
observed basal cell state across metagene 10 (“paracrine response”) for each sample versus the 
predicted values based on multiple linear regression analysis with three predictors: HR+ cell hormone 
signaling (HR+ metagene 8), the frequency of HR+ cells in the epithelium, and an interaction term 
representing the combined effects of HR+ cell signaling and frequency (Signaling × Frequency). (B) 
Ridge plots depicting the distribution of HR+ cell metagene 8 (“hormone signaling”) expression across 
samples, and quantification of the average expression in obese (BMI > 30) versus non-obese (BMI ≤ 30) 
samples (n = 16 samples, p < 0.31, Mann-Whitney test). (C) Ridge plots depicting the distribution of basal 
cell metagene 10 (“paracrine response”) expression across samples, and quantification of the average 
expression in nulliparous (NP) versus parous (P) samples (n = 22 samples, p < 0.003, Mann-Whitney 
test). (D) Volcano plot highlighting genes downregulated in basal/myoepithelial cells in both parous and 
obese samples. 
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Supplemental Tables 
 
Table S1. Donor information for reduction mammoplasty samples and list of samples used for scRNAseq, 
FACS, and immunostaining experiments.  
 
Table S2. Summary statistics for single-cell RNA sequencing of twenty-eight reduction mammoplasty 
samples and seven Komen Tissue Bank samples.  
 
Table S3. Multiple linear regression analysis of the percentage of basal cells in the epithelium as 
measured by FACS.  
 
Table S4. Association of the 20 highest-loading genes in PC1 for HR+ luminal cells with estrogen 
signaling, progesterone signaling, or the luteal phase of the menstrual cycle. 
 
Table S5. Canonical hormone-responsive genes differentially expressed in HR+ luminal cells between 
parous and nulliparous samples.  
 
Table S6. Multiple linear regression analysis of the basal paracrine response (metagene 10) in response 
to three predictors: HR+ cell hormone signaling (HR+ metagene 8), the frequency of HR+ cells in the 
epithelium, and an interaction term representing the combined effects of HR+ signaling and frequency 
(Signaling × Frequency) 
 
Table S7. Genes differentially expressed in basal cells between parous versus nulliparous samples or 
obese (BMI >30) versus non-obese (BMI < 30) samples. 
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